Clinical Trial Update: A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients [Phase 3]

View source ↗

Summary

Phase III trial comparing niraparib to physician's choice in HER2-negative, germline BRCA mutation–positive breast cancer terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Neoplasms

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Neoplasms, Breast, Carcinoma of Breast | Phase 3 | Status: TERMINATED | Results posted: 2020-08-27